EKSO BIONICS HOLDING (OTCBB:EKSO) comes in the list of new companies active in digital technology industry. The company owns a product that can excel into a number of different industries like consumer, military and healthcare.
Trading at $1.44 per share with an average volume of 535,883, the company designs wearable bionic exoskeletons that improve human strength, endurance, and mobility. It is a unique product that can be used for multiple purposes like aiding the disabled or enhancing the use of military tactics. Ekso Bionics gained traction with a latest software upgrade earlier in the year, and its CEO featuring on FOX Business Network in August.
Ekso Bionics recorded an impressive performance in the second half of August after it briefly declined below $1 mark on August 17, touching its lowest trading prices since the start of the year. The stock not only managed to recoup its losses but strongly made its way up on the chart, reaching as high as $1.45 on August 27, 2015.
This impressive run on the chart came without an analyst article or a promising press release coming from the company. It is not at all surprising, accounting the strong financial figures that EKSO Bionics has to offer in 2Q2015 report.
The number game
As per the latest report, the cash reserves stood at $16.2 million and current assets were no less than $22.1 million. The current liabilities at the end of 2Q stood at $8.3 million while revenue and net loss came at $2.1 million and $5.6 million, respectively. Still, at these levels, the market capitalization of the company is more than $138 million, which suggests a caution before putting in more money in EKSO BIONICS HOLDING (OTCBB:EKSO) stock. After a red close last week, the stock closed in green on Monday but closed in deep red in following sessions.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: